磁共振成像技术在脑转移瘤诊断和疗效评估方面的研究进展

doi:10.3969/j.issn.1674-490X.2026.01.003

摘要/Abstract

摘要： 脑转移瘤(brain metastasis, BM)是起源于中枢神经系统外实体器官的继发性恶性肿瘤,是系统性癌症的不可治愈晚期阶段的严重并发症,肿瘤高度多样化、高异质性且预后差,比原发性脑肿瘤更常见。BM的早期精准诊断以及对其治疗预后的准确评估,对于BM的临床决策至关重要。目前,BM的诊断分类主要依赖于影像学资料和临床病史,而磁共振成像(magnetic resonance imaging,MRI)因其高度敏感度和特异度,常规增强MRI成为无创诊断BM的影像学金标准,在BM的早期诊断、治疗方案的制定方面优势突出。随着MRI技术的不断发展,影像学诊断在BM的诊断、评估和治疗中展现出巨大的潜力,新兴MRI技术不只局限于从形态学评估BM,功能MRI技术进一步从分子生物水平无创评估BM状况,从而促进精准高效的诊断和提高疗效评估的准确性、效率,有助于临床决策。

关键词: 脑转移瘤, 磁共振成像, 功能磁共振成像

Abstract: Brain metastasis(BM)are secondary malignant tumors originating from solid organs outside the central nervous system. They represent a severe complication of the incurable advanced stage of systemic cancer, characterized by high diversity, high heterogeneity, and poor prognosis, and are more common than primary brain tumors. The early and precise diagnosis of BM as well as the accurate assessment of their treatment prognosis are of critical importance for clinical decision-making regarding BM. The diagnostic classification of BM primarily relies on imaging data and clinical history. Due to its high sensitivity and specificity, conventional enhanced magnetic resonance imaging(MRI)has become the radiological gold standard for noninvasive diagnosis of BM, offering significant advantages in early diagnosis and treatment planning. Imaging diagnostics have shown great potential in the diagnosis, assessment and treatment of brain BM with the continuous development of MRI technology. Imaging diagnosis has demonstrated enormous potential in the diagnosis, evaluation and treatment of BM with the continuous advancement of MRI technology. Emerging functional MRI techniques are not confined to morphological assessment of BM; functional MRI technologies enable non-invasive evaluation of BM at the molecular and biological levels. This advancement facilitates precise and efficient diagnosis, enhances the accuracy and efficiency of therapeutic efficacy assessment and aids in clinical decision-making. This article reviews the application and latest research progress of MRI in the diagnosis and efficacy assessment of brain metastasis.

Key words: brain metastasis, magnetic resonance imaging, functional magnetic resonance imaging

中图分类号:

隋莲玉,邢立红,王佳宁,殷小平. 磁共振成像技术在脑转移瘤诊断和疗效评估方面的研究进展[J]. 医学研究与教育, 2026, 43(1): 20-34.

SUI Lianyu, XING Lihong, WANG Jianing, YIN Xiaoping. Advances on magnetic resonance imaging for the diagnosis and therapeutic evaluation of brain metastasis[J]. Journal of Hebei Medical College for Continuing Education, 2026, 43(1): 20-34.

参考文献

[1] SUNG K S. Clinical practice guidelines for brain metastasis from solid tumors[J]. Brain Tumor Res Treat, 2024, 12(1): 14-22. DOI: 10.14791/btrt.2023.0049.
[2] LAMBA N, WEN P Y, AIZER A A. Epidemiology of brain metastases and leptomeningeal disease[J]. Neuro Oncol, 2021, 23(9): 1447-1456. DOI: 10.1093/neuonc/noab101.
[3] ALSABBAGH R, AHMED M, ALQUDAH M A Y, et al. Insights into the molecular mechanisms mediating extravasation in brain metastasis of breast cancer, melanoma, and lung cancer[J]. Cancers(Basel), 2023, 15(8): 2258. DOI: 10.3390/cancers15082258.
[4] SASAKI T, KUNO H, HIYAMA T, et al. 2021 WHO classification of lung cancer: molecular biology research and radiologic-pathologic correlation[J]. Radiographics, 2024, 44(3): e230136. DOI: 10.1148/rg.230136.
[5] BEJARANO L, KAUZLARIC A, LAMPROU E, et al. Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms[J]. Cancer Cell, 2024, 42(3): 378-395. DOI: 10.1016/j.ccell.2023.12.018.
[6] WAIZMAN E, DUDNIK E, LAVIE I, et al. The impact of brain MRI screening on stage Ⅳ NSCLC patients: a real world look at guidelines based care[J]. J Neurol Sci, 2025, 470: 123398. DOI: 10.1016/j.jns.2025.123398.
[7] DREGELY I, PREZZI D, KELLY-MORLAND C, et al. Imaging biomarkers in oncology: basics and application to MRI[J]. J Magn Reson Imaging, 2018, 48(1): 13-26. DOI: 10.1002/jmri.26058.
[8] FAN B, LI M J, WANG X Y, et al. Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases[J]. J Magn Reson Imaging, 2017, 45(6): 1827-1834. DOI: 10.1002/jmri.25491.
[9] LE RHUN E, GUCKENBERGER M, SMITS M, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours[J]. Ann Oncol, 2021, 32(11): 1332-1347. DOI: 10.1016/j.annonc.2021.07.016.
[10] 朱冬, 汤若琪, 徐金娥, 等. MRI三期增强扫描对脑转移瘤的诊断价值[J]. 现代肿瘤医学, 2023, 31(3): 513-516. DOI: 10.3969/j.issn.1672-4992.2023.03.024.
[11] 曹明慧, 苏赟, 苏卫锋, 等. 钆对比剂剂量对增强T2-FLAIR序列与增强T1WI序列脑转移瘤强化效果的影响及对比研究[J]. 磁共振成像, 2024, 15(1): 152-157. DOI: 10.12015/issn.1674-8034.2024.01.024.
[12] 陈龙凤, 罗文明. 3.0 T磁共振T2-FLAIR增强对比T1WI增强在脑转移诊断中的价值[J]. 中国当代医药, 2023, 30(29): 116-119. DOI: 10.3969/j.issn.1674-4721.2023.29.027.
[13] PARILLO M, VERTULLI D, VACCARINO F, et al. The sensitivity of MIPs of 3D contrast-enhanced VIBE T1-weighted imaging for the detection of small brain metastases(≤5 mm)on 1.5 tesla MRI[J]. Neuroradiol J, 2024, 37(6): 744-750. DOI: 10.1177/19714009241260802.
[14] HEYN C, BISHOP J, MOODY A R, et al. Gadolinium-enhanced T2-FLAIR is an imaging biomarker of radiation necrosis and tumor progression in patients with brain metastases[J]. AJNR Am J Neuroradiol, 2025, 46(1): 129-135. DOI: 10.3174/ajnr.A8431.
[15] 李怀花, 梁雪, 田传帅, 等. 不同3D MRI增强扫描序列在脑转移瘤检出中的价值[J]. 中国中西医结合影像学杂志, 2025, 23(2): 257-261. DOI: 10.3969/j.issn.1672-0512.2025.02.024.
[16] ZHOU Z H C, SALVADOR ÁLVAREZ E, HILARIO A, et al. Improved detection of brain metastases using contrast-enhanced 3D black-blood TSE sequences compared to post-contrast 3D T1 GRE: a comparative study on 1.5-T MRI[J]. Eur Radiol, 2025. DOI: 10.1007/s00330-025-11363-0.
[17] SHUKLA S, KARBHARI A, RASTOGI S, et al. Bench-to-bedside imaging in brain metastases: a road to precision oncology[J]. Clin Radiol, 2024, 79(7): 485-500. DOI: 10.1016/j.crad.2024.02.015.
[18] ZHU D, SHAO Y J, YANG Z W, et al. Magnetic resonance imaging characteristics of brain metastases in small cell lung cancer[J]. Cancer Med, 2023, 12(14): 15199-15206. DOI: 10.1002/cam4.6206.
[19] 王玉瑶, 杨洋, 乔书琪, 等. 常规MRI分形分析鉴别胶质母细胞瘤与孤立性脑转移瘤[J]. 放射学实践, 2024, 39(11): 1442-1447. DOI: 10.13609/j.cnki.1000-0313.2024.11.003.
[20] OCAÑA-TIENDA B, PÉREZ-BETETA J, ORTIZ DE MENDIVIL A, et al. Morphological MRI features as prognostic indicators in brain metastases[J]. Cancer Imaging, 2024, 24(1): 111. DOI: 10.1186/s40644-024-00753-0.
[21] ARMOCIDA D, ZANCANA G, BIANCONI A, et al. Brain metastases: comparing clinical radiological differences in patients with lung and breast cancers treated with surgery[J]. World Neurosurg X, 2024, 23: 100391. DOI: 10.1016/j.wnsx.2024.100391.
[22] 佟滨, 张志南. 肺癌脑转移瘤的MRI影像特征与病理组织学的相关性分析[J]. 航空航天医学杂志, 2024, 35(7): 782-785. DOI: 10.3969/j.issn.2095-1434.2024.07.006.
[23] MOHAMMADI M, MOHAMMADI S, HADIZADEH H, et al. Brain metastases from breast cancer using magnetic resonance imaging: a systematic review[J]. J Med Radiat Sci, 2024, 71(1): 133-141. DOI: 10.1002/jmrs.715.
[24] YOUNG J R, RESSLER J A, MORTIMER J E, et al. Association of lesion contour and lesion composition on MR with HER2 status in breast cancer brain metastases[J]. Magn Reson Imaging, 2023, 96: 60-66. DOI: 10.1016/j.mri.2022.11.009.
[25] VISONÀ G, SPILLER L M, HAHN S, et al. Machine-learning-aided prediction of brain metastases development in nonsmall-cell lung cancers[J]. Clin Lung Cancer, 2023, 24(8): e311-e322. DOI: 10.1016/j.cllc.2023.08.002.
[26] REN X L, ZHANG X T, LEI X Y, et al. Comparison of clinical and MRI features of brain metastases between ALK+ and ALK- NSCLC[J]. Cancer Med, 2024, 13(11): e7405. DOI: 10.1002/cam4.7405.
[27] ZHANG X, YANG J, HU H, et al. Longitudinal MRI evaluation of the efficacy of non-enhanced lung cancer brain metastases[J]. Sci Rep, 2025, 15(1): 3318. DOI: 10.1038/s41598-025-87422-9.
[28] XU Y B, ZHANG Y P, SONG Z B, et al. Treatment and prognosis of solid and cystic brain metastases in patients with nonsmall-cell lung cancer[J]. Cancer Manag Res, 2021, 13: 6309-6317. DOI: 10.2147/CMAR.S314060.
[29] MÜLLER S J, KHADHRAOUI E, ERNST M, et al. Differentiation of multiple brain metastases and glioblastoma with multiple foci using MRI criteria[J]. BMC Med Imaging, 2024, 24(1): 3. DOI: 10.1186/s12880-023-01183-3.
[30] MA L H, XU G F, BALZANO R F, et al. The value of DTI: achieving high diagnostic performance for brain metastasis[J]. Radiol Med, 2021, 126(2): 291-298. DOI: 10.1007/s11547-020-01243-6.
[31] GHADERI S, MOHAMMADI S, FATEHI F. Diffusion tensor imaging(DTI)biomarker alterations in brain metastases and comparable tumors: a systematic review of DTI and tractography findings[J]. World Neurosurg, 2024, 190: 113-129.DOI: 10.1016/j.wneu.2024.07.037.
[32] HE L B, CHEN M N, LI H J, et al. Differentiation between high-grade gliomas and solitary brain metastases based on multidiffusion MRI model quantitative analysis[J]. Front Oncol, 2024, 14: 1401748. DOI: 10.3389/fonc.2024.1401748.
[33] WÜRTEMBERGER U, RAU A, DIEBOLD M, et al. Advanced diffusion MRI provides evidence for altered axonal microstructure and gradual peritumoral infiltration in GBM in comparison to brain metastases[J]. Clin Neuroradiol, 2024, 34(3): 703-711. DOI: 10.1007/s00062-024-01416-0.
[34] 王嫚, 苗延巍. 高级别胶质瘤与脑转移瘤鉴别的多序列磁共振成像研究进展[J]. 磁共振成像, 2025, 16(2): 159-164. DOI: 10.12015/issn.1674-8034.2025.02.026.
[35] AZAB M A, EL-GOHARY N, ATALLAH O, et al. Perfusion-MRI for differentiating cerebral metastatic lesions and gliomas: an evidence-based review[J]. J Clin Neurosci, 2025, 133: 111036. DOI: 10.1016/j.jocn.2025.111036.
[36] MOHAMMADI S, GHADERI S, JOUZDANI A F, et al. Differentiation between high-grade glioma and brain metastasis using cerebral perfusion-related parameters(cerebral blood volume and cerebral blood flow): a systematic review and meta-analysis of perfusion-weighted MRI techniques[J]. J Magn Reson Imaging, 2025, 61(2): 758-768. DOI: 10.1002/jmri.29473.
[37] LOIZZO S K, PRAH M A, KONG M J, et al. Multisite benchmark study for standardized relative CBV in untreated brain metastases using the DSC-MRI consensus acquisition protocol[J]. AJNR Am J Neuroradiol, 2025, 46(3): 529-535. DOI: 10.3174/ajnr.A8531.
[38] 王旭, 魏强, 刘义军, 等. 肺癌脑转移瘤DSC-PWI: ASL最佳标记延迟时间分析[J]. 放射学实践, 2023, 38(4): 394-400. DOI: 10.13609/j.cnki.1000-0313.2023.04.005.
[39] 郭欣欣, 张军, 王晓雨, 等. 磁共振3D-ASL联合DTI技术对脑转移瘤放射治疗疗效的评估价值[J]. 生命科学仪器, 2024, 22(4): 31-33. DOI: 10.11967/2024220811.
[40] SCHACK A, AUNAN-DIOP J S, GERHARDT F A, et al. Evaluating the efficacy of perfusion MRI and conventional MRI in distinguishing recurrent cerebral metastasis from brain radiation necrosis[J]. Brain Sci, 2024, 14(4): 321. DOI: 10.3390/brainsci14040321.
[41] OSTOJIC J, KOZIC D, PANJKOVIC M, et al. Peak resembling N-acetylaspartate(NAA)on magnetic resonance spectroscopy of brain metastases[J]. Medicina(Kaunas), 2024, 60(4): 662. DOI: 10.3390/medicina60040662.
[42] 索红娜, 李艳翠, 彭如臣. 1H-MRS联合DTI在脑高级别胶质瘤与转移瘤鉴别诊断中的应用探讨[J]. 磁共振成像, 2023, 14(12): 103-108, 120. DOI: 10.12015/issn.1674-8034.2023.12.017.
[43] MARTÍN-NOGUEROL T, SANTOS-ARMENTIA E, RAMOS A, et al. An update on susceptibility-weighted imaging in brain gliomas[J]. Eur Radiol, 2024, 34(10): 6763-6775. DOI: 10.1007/s00330-024-10703-w.
[44] 吴立业, 蒋锡丽, 黄子龙, 等. SWI在不同病理类型肺癌脑转移瘤诊断中的应用[J]. 中国CT和MRI杂志, 2023, 21(4): 55-57. DOI: 10.3969/j.issn.1672-5131.2023.04.020.
[45] 吴立业, 罗文明, 蒋锡丽, 等. 对比增强SWI对不同病理类型肺癌脑转移瘤的诊断价值[J]. 放射学实践, 2024, 39(1): 55-59. DOI: 10.13609/j.cnki.1000-0313.2024.01.010.
[46] 李姝毅, 何庄超, 郑海军, 等. 磁敏感加权成像对脑转移瘤放疗后疗效评价[J]. 中国CT和MRI杂志, 2025, 23(2): 25-28. DOI: 10.3969/j.issn.1672-5131.2025.02.008.
[47] 叶华景, 胡海菁, 谭树生, 等. 磁敏感加权成像联合磁化传递对比技术对出血性脑转移瘤的诊断价值[J]. 中国CT和MRI杂志, 2025, 23(3): 12-14. DOI: 10.3969/j.issn.1672-5131.2025.03.005.
[48] KNUTSSON M, SALOMONSSON T, DURMO F, et al. Differentiation between glioblastoma and solitary brain metastases using perfusion and amide proton transfer weighted MRI[J]. Front Neurosci, 2025, 19: 1533799. DOI: 10.3389/fnins.2025.1533799.
[49] XIANG X Y, LI X Z, LIN H T, et al. Amide proton transfer-weighted MRI in predicting pathological types of brain metastases in lung Cancer[J]. Magn Reson Imaging, 2024, 108: 59-66. DOI: 10.1016/j.mri.2024.01.014.
[50] KAS A, ROZENBLUM L, PYATIGORSKAYA N. Clinical value of hybrid PET/MR imaging: brain imaging using PET/MR imaging[J]. Magn Reson Imaging Clin N Am, 2023, 31(4): 591-604. DOI: 10.1016/j.mric.2023.06.004.
[51] HUSBY T, JOHANNESSEN K, BERNTSEN E M, et al. ¹⁸F-FACBC and ¹⁸F-FDG PET/MRI in the evaluation of 3 patients with primary central nervous system lymphoma: a pilot study[J]. EJNMMI Rep, 2024, 8(1): 2. DOI: 10.1186/s41824-024-00189-6.
[52] ROSEN J, WERNER J M, CECCON G S, et al. MRI and ¹⁸F-FET PET for multimodal treatment monitoring in patients with brain metastases: a cost-effectiveness analysis[J]. J Nucl Med, 2024, 65(6): 838-844. DOI: 10.2967/jnumed.123.266687.
[53] IVANIDZE J, SHARBATDARAN A, MCCALLA A, et al. [18F] -Fluoroestradiol(FES)brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases[J]. Eur J Radiol, 2024, 181: 111791. DOI: 10.1016/j.ejrad.2024.111791.